We're delighted to welcome Yao Zhu, MD, PhD, as a Consulting Editor for European Urology. A leader in genitourinary oncology, robotic surgery, and translational research, Professor Zhu brings extensive clinical, research, and editorial experience to our team. Welcome aboard! #EuropeanUrology #Urology #Oncology

A Great Start to Day Two of #ASCO26 and no better way to start than our @OncoAlert 🚨from the Podium to your feed with Dr. Elizabeth Nally from Barts Cancer institute🇬🇧 discussing Abstract 4512 : Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma. In this multicentre London study of 104 patients with RCC treated with adjuvant pembrolizumab, decision regret was uncommon (13%) after a median 30-month follow-up. Regret was driven primarily by long-term, patient-perceived significant or life-changing toxicities rather than disease recurrence or CTCAE-graded severity. Permanent endocrine and musculoskeletal toxicities were associated with the highest regret. Patient-informed toxicity assessments outperformed CTCAE criteria in identifying regret, highlighting the importance of patient education and shared decision-making. #KidneyCancer Elizabeth Nally @veda13k @scocmem @b_szabados @Naveed_Sarwar @tompowles1 @montypal @crisbergerot Pinging OncoAlert Faculty @brian_rini 🇺🇸@declangmurphy 🇦🇺 @KidneyCancer 🇺🇸 @salvolarosa @silkegillessen🇨🇭 @APCCC_Lugano @RenuEapen 🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @DrJaVallejo 🇪🇸 Pinging our ASCO Pulse Faculty @DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

A HUGE Round of thanks! The #OncoAlert5k 🚨Continues to Grow year after year, with a lot of new faces but also all the regulars🏃‍♂️ Thank you all of the great support! WE ARE INDEED ALL OncoAlert!! @Icro_Meattini @BalazsHalmosMD @alitimumab @MikeSerzanMD @barrosonco @DrVilmaPBarcia @DonjetaZeqa @crisonco @santcancela @golbretas @fedenichetti @crisonco @CathyEngMD @BenWestphalen @OncBrothers @graokane @realbowtiedoc @GaiaGriguolo @COR2EDMedEd @mirrorsmed @amerseburger @DrMirallas @ravikanesvaran @fabioturco92 @salvolarosa @KidneyCancer We Totally missed @to_be_elizabeth @ElisaAgostinett @nataliagandur and @CentralParkWMD @Latinamd @CathyEngMD @LaurenMachos @JooMouta2 @drteplinsky @matteolambe and many more but we look forward to seeing them at the 5k in Madrid🇪🇸 or during OUR HOMECOMING 5k in my HOME of San Antonio Tx🇺🇸for #SABCS26

Dear Colleagues at #ASCO26 A Great pleasure to bring you from the podium to your feed our amazing GU Faculty Dr. Tom Powles 🇬🇧presenting EV302 With 3.5 years of follow-up, EV plus pembrolizumab continues to demonstrate durable survival benefits over platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Median overall survival reached 33.6 months versus 15.9 months with chemotherapy, without new safety signals. Notably, two-thirds of patients achieving complete response initially had partial responses, often converting after additional treatment cycles, highlighting the importance of treatment duration in maximizing long-term outcomes. asco.org/abstracts-presentat… @tompowles1 @MichvdHeijden @MattGalsky @y_loriot @IyerGopa @JCensits @mar_nataliya @CVulsteke @KalaSridh @shilpaonc @OncoAlert @nataliagandur @scocmem @AmandaNizamMD @WeOncologists @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini @weoncologists